R&D Bioanalytical labs need to reimagine data to streamline thei... The fundamental questions in the trial phases of drug development are “Does it work?”, “Is it safe?”, and “What else do we need to know?”
News Syndax gets FDA okay for first-in-class leukaemia drug A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.